A Prospective, Multicentric Study, To Evaluate The Effectiveness And Safety Of Milk Of Magnesia+Liquid Paraffin+Sodium Picosulfate In The Treatment Of Constipation Symptoms In Post Ano-Rectal Surgical Patients - NA

开始日期2024-07-29

申办/合作机构

Abbott India Ltd.

TCTR20230816005

/ Recruiting临床2/3期IIT

The effects of milk of magnesia for prevention post-operative ileus after hysterectomy: A randomized controlled trial

开始日期2023-09-25

申办/合作机构-

NCT05216328

/ Recruiting临床4期IIT

OMAMA-study - Prevention of Opioid-induced Constipation in Patients With Advanced Cancer

More than 70% of patients with cancer in the palliative phase have pain that often requires treatment with opioids (morphine-like agents). Constipation occurs in 59% of patients treated with opioids. Opioid-induced constipation (OIC) has consequences that range from daily discomfort with social insecurity and disability to intestinal obstruction. It leads to limitations in self-management, a reduced quality of life and a risk of the need for more care. In the guideline "Diagnosis and treatment of pain in patients with cancer" it is recommended to start preventively with an osmotic laxative such as macrogol/electrolytes or magnesium hydroxide when starting opioids. Macrogol/electrolytes has been proven to be effective for OIC, but is sometimes perceived by patients as unpleasant due to its taste. Magnesium hydroxide, which is less commonly prescribed for OIC, has a neutral taste. Although it is mentioned in the guideline, it is not studied for the treatment of OIC and also not officially registered for this. To support the advice of the guideline and to prove that a choice is possible, it is important to investigate whether there are differences in effectiveness and/or side effects between macrogol/electrolytes and magnesium hydroxide in the prevention of OIC.
The aim of this study is to compare macrogol/electrolytes with magnesium hydroxide in the prevention of opioid-induced constipation in patients with cancer in the palliative (incurable) phase, who start opioids because of pain. The choice of laxative is determined by drawing lots (randomisation). After two weeks, its effect will be assessed and will be presented as the percentage of patients who have not developed constipation after starting opioids. If the laxative, as assigned by lot, is described as satisfactory by the patient, the patient can continue with the drug that the patient used, after the study through regular prescription.
The investigators will ask the patients in the study about their satisfaction with the laxative used, any side effects and the degree of pain. Furthermore, the appeal to care for possible constipation will be examined. Because the best attainable quality of life in the palliative phase is the objective of all care, the investigators will also measure this perceived quality with a questionnaire in this study. The results of this study will lead to the best achievable prevention of opioid constipation in patients with cancer in the palliative phase.

开始日期2022-12-02

申办/合作机构

Stichting Onderzoek Cancer Center Amsterdam

[+12]

100 项与氢氧化镁相关的临床结果

登录后查看更多信息

100 项与氢氧化镁相关的转化医学

登录后查看更多信息

100 项与氢氧化镁相关的专利（医药）

登录后查看更多信息

15,513

项与氢氧化镁相关的文献（医药）

2025-07-01·SEPARATION AND PURIFICATION TECHNOLOGY

A highly selective and low-discharge method for vanadium extraction from vanadium slag: Low-calcification roasting-sodium bicarbonate leaching

作者: Rao, Yuzhong ; Wang, Shiwei ; He, Wenyi ; Fu, Zibi ; Wang, Ning ; Du, Guangchao

The current industrial processes for vanadium extraction from vanadium slag have common disadvantages, e.g., weak selectivity of vanadium and impurities (especially chromium), significant amounts of solid waste from wastewater treatment, and low utilization of the residue.This study proposes a new method featuring low-calcification roasting-sodium bicarbonate (NaHCO₃) leaching for vanadium extraction from vanadium slag.Theor. analyses, process optimization, and characterizations were conducted for this method.Vanadium was selectively transformed into calcium pyrovanadate, manganese pyrovanadate and magnesium pyrovanadate by roasting the vanadium slag with added calcium oxide (3% by mass) at 900 °C for 100 min.Then, vanadium was leached into solution by NaHCO₃ at 95 °C for 120 min, resulting in vanadium and chromium leaching rates of 94.24% and 0.01%, resp.The leaching residue exhibited sulfur and sodium contents of 0.005% and 0.57%, which has well potential for further utilization via recycling to blast furnaces.Subsequently, ammonium metavanadate (NH₄VO₃) was obtained by vanadium precipitation from the leaching solution with ammonium carbonate as an additive.The wastewater generated after vanadium precipitation could be directly recycled to the next round of leaching.Finally, vanadium pentoxide with a purity of 99.61% was obtained by calcination of NH₄VO₃.This method has significant advantages of higher selectivity of vanadium extraction, minimization of solid waste, and higher potential for residue recycling.It provides a new insights for clean and efficient vanadium extraction as well as resources comprehensive utilization of vanadium slag.

2025-07-01·SEPARATION AND PURIFICATION TECHNOLOGY

Facile and low-cost method for preparing multilayer ceramic membranes based on cordierite and abundant clay: Application to dye removal

作者: Waqif, Mohamed ; Tabit, Kamal ; Boutaleb, Mouhssine ; Mansori, Mohammed ; Saadi, Latifa

Textile dyes represent a growing source of environmental pollution worldwide, affecting aquatic ecosystems and, by extension, human health.This study aims to develop low-cost ceramic membranes for the treatment of water contaminated by these dyes, using natural and economical materials.The membranes were made from abundant clay with different mass percentages of magnesium hydroxide, used as a pore-forming agent and were sintered at 900 °C and 1000 °C.To enhance filtration performance, the membranes were coated with a chem., phys., and thermally stable layer of refractory cordierite phase.This was achieved using a sedimentation technique, which allowed precise control overthe thickness and ensured the formation of a thin, homogeneous layer.The microstructural evolution of the membranes was examined using XRF, XRD, SEM, and DTA-TGA techniques, while their properties were assessed through measurements of flux, permeability, porosity, d., and mech. strength.Filtration performance was evaluated using a methylene blue solutionThe results indicated that membranes sintered at 900 °C effectively filtered 99 % to 99.8 % of dyes, achieving fluxes between 46.36 and 84 L/(h·m²), with mech. strengths ranging from 79 to 113 MPa.For membranes sintered at 1000 °C with 5 % magnesium hydroxide, filtration performance improved from 50 % to 99 % with the addition of a cordierite layer, resulting in fluxes between 61 and 77 L/(h·m²) and compressive strengths from 60 MPa to 136 MPa.Production costs for ceramic membranes are estimated at around 12 to 46 USD/m², due to the use of low-cost materials and reduced sintering temperaturesThe incorporation of the cordierite layer enhances the membranes′ suitability for demanding environments.

2025-07-01·JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY A-CHEMISTRY

A new application for simultaneous phosphorus compounds removal and antibiotics degradation over magnesium-based layered double hydroxides

作者: Zhou, Hao ; Xiang, Wenlong ; Zhang, Yanhui ; Zheng, Yisha

Magnesium-based layered double hydroxides (MgM-LDHs, M = Al, Ga, In) were synthesized by one-step coprecipitation method, which is a simple and mass-production method.The catalytic performance of MgAl-LDHs, MgGa-LDHs and MgIn-LDHs in the photocatalytic degradation of antibiotics (ciprofloxacin and tetracycline hydrochloride) was systematically investigated.The results showed that the photocatalytic activities of MgAl-LDHs, MgGa-LDHs and MgIn-LDHs were comparable, but MgAl-LDHs exhibited superior degradation efficiency of antibiotics.Through control experiments, the possible mechanism of photocatalytic degradation of antibiotics by MgAl-LDHs was elucidated.Furthermore, it was observed that the adsorption of phosphorus compounds by MgAl-LDHs significantly enhances its photocatalytic activity in degrading ciprofloxacin.This finding suggests that incorporating phosphorus compounds into MgAl-LDHs can improve their efficacy in water pollution control.Overall, our work extends the application scope of MgM-LDHs (M = Al, Ga, In) and underscore the significance of active participation in water pollution control research to mitigate adverse effects on human health.

项与氢氧化镁相关的新闻（医药）

2024-01-02

·SYNAPSE

Demystifying H2 receptor antagonists: A Comprehensive Guide and How to Keep Up with the Latest Developments

The H2 receptor, also known as the histamine H2 receptor, plays a crucial role in the human body. It is primarily found in the stomach lining and is responsible for regulating the production of gastric acid. Activation of the H2 receptor by histamine leads to an increase in acid secretion, which aids in the digestion of food. However, excessive acid production can lead to conditions like gastric ulcers and gastroesophageal reflux disease (GERD). Therefore, pharmaceutical companies have developed H2 receptor antagonists, commonly known as H2 blockers, to inhibit the receptor's activity and reduce acid secretion, providing relief from acid-related disorders. Looking forward, the future of H2 receptor antagonists appears promising. Recent studies suggest that H2 receptor antagonists show significant promise as radioprotective agents. They could potentially be used for providing partial protection against radiation injury. Furthermore, there is ongoing research into repurposing H2 receptor antagonists for other uses. The global H2-receptor antagonists market is anticipated to grow at a substantial CAGR in the upcoming years. These developments suggest that H2 receptor antagonists could play a significant role in the treatment of various diseases in the future. The analysis of the target H2 receptor reveals a competitive landscape with multiple companies focusing on the development of drugs for various indications related to gastrointestinal disorders. GSK Plc is leading in terms of the highest number of drugs in the approved stage. Small molecule drugs are the most common drug type, indicating intense competition. China, the United States, Japan, and South Korea are the countries/locations with the highest development progress. China, in particular, has made significant progress in the development of drugs for the target H2 receptor. The future development of the target H2 receptor is expected to continue with a focus on innovative small molecule drugs and biosimilars, particularly in the treatment of gastrointestinal disorders. How do they work?H2 receptor antagonists, also known as H2 blockers, are a class of drugs that inhibit the action of histamine on the H2 receptors in the stomach. Histamine is a chemical released by cells in the stomach lining and stimulates the production of stomach acid. By blocking the H2 receptors, H2 receptor antagonists reduce the production of stomach acid, thereby decreasing acid-related symptoms and promoting healing of certain gastrointestinal conditions. From a biomedical perspective, H2 receptor antagonists are commonly used in the treatment of conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and gastritis. These drugs help alleviate symptoms like heartburn, acid reflux, and stomach pain by reducing the amount of acid produced in the stomach. They are often prescribed as a first-line treatment for these conditions and are available both over-the-counter and by prescription. Examples of H2 receptor antagonists include famotidine, ranitidine, and cimetidine. These drugs work by binding to the H2 receptors on the surface of stomach cells, preventing histamine from binding and triggering acid production. By reducing gastric acid secretion, H2 receptor antagonists provide relief from acid-related symptoms and promote the healing of damaged stomach lining. It's important to note that while H2 receptor antagonists are effective in managing certain gastrointestinal conditions, they may not be suitable for everyone. Individuals with certain medical conditions or taking specific medications should consult with their healthcare provider before using H2 receptor antagonists. Additionally, prolonged use of these drugs may have some side effects, such as headaches, dizziness, and diarrhea. Therefore, it is essential to follow the recommended dosage and duration of treatment as advised by a healthcare professional. List of H2 receptor AntagonistsThe currently marketed H2 receptor antagonists include: Ranitidine Hydrochloride/Bismuth Potassium Citrate/SucralfateFamotidine/IbuprofenRanitidine Hydrochloride/Bismuth Potassium CitrateRoxatidine Acetate HydrochlorideFamotidine/magnesium dihydroxide/Calcium carbonateLafutidineRanitidine Bismuth CitrateNizatidineFamotidineRanitidine HydrochlorideFor more information, please click on the image below. What are H2 receptor antagonists used for?H2 receptor antagonists are commonly used in the treatment of conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and gastritis. For more information, please click on the image below to log in and search. How to obtain the latest development progress of H2 receptor antagonists?In the Synapse database, you can keep abreast of the latest research and development advances of H2 receptor antagonists anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

100 项与氢氧化镁相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00731	-	-	DB09104

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
便秘	日本	MG Pharma Co. Ltd.	1952-10-08
十二指肠溃疡	日本	MG Pharma Co. Ltd.	1952-10-08
胃炎	日本	MG Pharma Co. Ltd.	1952-10-08
胃溃疡	日本	MG Pharma Co. Ltd.	1952-10-08

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胃食管反流	临床3期	波兰	諾金有限公司	2011-04-01
胃灼热	临床3期	保加利亚	-	-
胃灼热	临床3期	捷克	-	-
胃灼热	临床3期	匈牙利	-	-
胃灼热	临床3期	英国	-	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASTRO2015	N/A	前列腺癌	-	Milk of Magnesia	壓餘鹽壓範願夢觸齋鹽(製選齋製衊鏇鑰淵廠遞) = n= 13/4 齋選鑰獵築糧簾襯觸蓋 (鑰淵衊鹹壓觸壓壓艱鹹 ) 更多	-	2015-11-01
				Milk of Magnesia (Simple dietary advice)